α-Glucosidase inhibitors have a prolonged antiviral effect against hepatitis B virus through the sustained inhibition of the large and middle envelope glycoproteins

Antiviral Chemistry and Chemotherapy

Volumn 17, Issue 5, 2006, Pages 259-267

  Simsek, Ender ^a   Lu, Xuanyong ^b   Ouzounov, Serguey ^b   Block, Timothy M ^b   Mehta, Anand S ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Antiviral; Glucosidase inhibitors; Glycosylation; Hepatitis B virus; Protein degradation

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA GLUCOSIDASE INHIBITOR; DEOXYNOJIRIMYCIN; ENVELOPE PROTEIN; GLYCOPROTEIN; LAMIVUDINE; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; ENZYME INHIBITION; GLYCOSYLATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; VIRION;

EID: 33845445964     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020601700503     Document Type: Article

References (28)

1. Abdelhamed AM, Kelley CM, Miller TG, Furman PA and Isom HC (2002). Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment. Journal of Virology 76:8148-8160.
2. Block TM, Lu X, Mehta AS, Blumberg BS, Tennant B, Ebling M, Korba B, Lansky DM, Jacob GS and Dwek RA (1998) Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nature Medicine 4:610-614.
3. Block TM, Lu X, Platt FM, Foster GR, Gerlich WH, Blumberg BS and Dwek RA (1994) Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proceedings of the National Academy of Sciences of the United States of America 91: 2235-2239.
4. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, Cavalli A, Urbani S, Boehme R, Panebianco R, Fiaccadori F and Ferrari C (2001) Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33:963-971.
5. Bruss V and Ganem D (1991) The role of envelope proteins in hepatitis B virus assembly. Proceedings of the National Academy of Sciences of the United States of America 88:1059-1063.
6. Courageot MP, Frenkiel MP, Dos Santos CD, Deubel V and Despres P (2000) Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. Journal of Virology 74:564-572.
7. Delaney WE 4th, Miller TG and Isom HC (1999) Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2′,3′-dideoxy-3′-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrobial Agents and Chemotherapy 43: 2017-2026.
8. Delaney WE 4th and Isom HC (1998) Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus Hepatology 28:1134-1146.
9. El-Serag HB, Mason AC and Key C (2001) Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 33:6265.
10. El-Serag HB and Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. New England Journal of Medicine 340:745-750.
11. Lu X, Lu Y, Geschwindt R, Dwek RA and Block TM (2001) Hepatitis B virus MHBs antigen is selectively sensitive to glucosidase-mediated processing in the endoplasmic reticulum. DNA and Cell Biology 20:647-656.
12. Lu X, Mehta A, Dadmarz M, Dwek R, Blumberg BS and Block TM (1997) Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited. Proceedings of the National Academy of Sciences of the United States of America 94:2380-2385.
13. Lu X, Mehta A, Dwek R, Butters T and Block T (1995) Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion. Virology 213:660-665.
14. Mehta A, Carrouee S, Conyers B, Jordan R, Butters T, Dwek RA and Block TM (2001) Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology 33:1488-1495.
15. Mehta A, Rudd PM, Block TM, and Dwek RA (1997a) A strategy for anti-viral intervention: the use of alpha-glucosidase inhibitors to prevent chaperone-mediated folding of viral envelope glycoproteins. Biochemical Society transactions 25:1188-1193.
16. Mehta A, Lu X, Block TM, Blumberg BS and Dwek RA (1997b) Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. Proceedings of the National Academy of Sciences of the United States of America 94:1822-1827.
17. Mehta A, Zitzmann N, Rudd PM, Block TM. and Dwek RA (1998) Alpha-glucosidase inhibitors as potential broad based anti-viral agents. FEBS Letters 430:17-22.
18. Menne S, Roneker CA, Tennant BC, Korba BE, Gerin JL and Cote PJ (2002) Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology 45:237-250.
19. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC and McDade H (1996) Viral dynamics in hepatitis B virus infection. Proceedings of the National Academy of Sciences of the United States of America 93:4398-4402.
20. Prange R, Werr M and Loffler-Mary H (1999) Chaperones involved in hepatitis B virus morphogenesis. Biological Chemistry 380:305-314.
21. Simsek E, Mehta A, Zhou T, Dwek RA and Block T (2005) Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme. Journal of Virology 79:12914-12920.
22. Tai PC, Suk FM, Gerlich WH, Neurath AR and Shih C (2002) Hypermodification and immune escape of an internally deleted middle-envelope (M) protein of frequent and predominant hepatitis B virus variants. Virology 292:44-58.
23. Tan A, van den Broek L, Bolscher J, Vermaas DJ, Pastoors L, van Boeckel C and Ploegh H (1994) Introduction of oxygen into the alkyl chain of N-decyl-dNM decreases lipophilicity and results in increased retention of glucose residues on N-linked oligosaccharides. Glycobiology 4:141-149.
24. Tan A, van den Broek L, van Boeckel S, Ploegh H and Bolscher J (1991) Chemical modification of the glucosidase inhibitor 1-deoxynojirimycin. Structure-activity relationships. Journal of Biological Chemistry 266: 14504-14510.
25. Wei, Y, Tavis, JE, Ganem, D (1996). 'Relationship between viral DNA synthesis and virion envelopment in hepatitis B virus.' Journal of Virology 70: 6455-6458.
26. Werr M and Prange R (1998) Role for calnexin and N-linked glycosylation in the assembly and secretion of hepatitis B virus middle envelope protein particles. Journal of Virology 72:778-782.
27. Whitby K, Pierson TC, Geiss B, Lane K, Engle M, Zhou Y, Doms RW and Diamond MS (2005) Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. Journal of Virology 79:8698-8706.
28. Whitby K, Taylor D, Patel D, Ahmed P and Tyms AS (2004) Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C. Antiviral Chemistry and Chemotherapy 15:141-151.